Abstract We have reported that inhibition of angiotensinconverting enzyme with captopril attenuates the cardiovascular responses to bilateral carotid occlusion in conscious rabbits and proposed that the attenuation results from removal of a facilitatory action of angiotensin II on the sympathetic nervous system. The aim of the present study was to assess the effect of carotid occlusion on renal sympathetic nerve activity in conscious rabbits and to investigate the effect of the angiotensin II subtype 1 (AT,) receptor antagonist losartan on the cardiovascular and renal sympathetic nerve activity responses to carotid occlusion. In seven conscious, aortic depressor nervesectioned rabbits, carotid occlusion elicited prompt and reproducible increases in mean arterial pressure from 75±2 to 124±5 mmHg (/ > <.001), heart rate from 285±8 to 317±9 beats per minute (P<.0l), and renal sympathetic nerve activity to 165±11% of control (P<.01). In the same rabbits, losartan (5 mg/kg IV) decreased mean arterial pressure by 9±2 mm Hg (/ > <.O1), increased renal sympathetic nerve activity to A ngiotensin II (Ang II) facilitates sympathetic ac-/ \ tivity by actions at the central and peripheral •i-JL. nervous systems, 13 but there is argument as to whether the facilitation occurs under physiological conditions 4 -5 or only when Ang II levels are elevated. 6 In a previous study 7 in this laboratory we observed that inhibition of the renin-angiotensin system with the angiotensin-converting enzyme inhibitor captopril markedly attenuated the pressor and heart rate responses to bilateral carotid occlusion (BCO). This attenuation could be reversed by replacement of Ang II in subpressor doses, suggesting that it resulted from inhibition of Ang II formation rather than from increased levels of kinins or vasodilator prostaglandins. We proposed that the attenuation resulted from removal of a presynaptic rather than a postsynaptic action of Ang II on the sympathetic nervous system, but beyond this, the site and mechanism of action of the Ang II was not identified.
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The aim of the present investigation was to further analyze the effect of inhibition of the renin-angiotensin system on the responses to BCO. This was accomplished by assessing the effect of BCO on renal sympathetic nerve activity (RSNA) in conscious rabbits and investigating the effect of the specific Ang II subtype 1 (ATi) receptor antagonist losartan on the cardiovascular and sympathetic nerve activity responses to BCO. 
Methods
Experiments were conducted in male New Zealand White rabbits weighing 2.7 to 3.3 kg using procedures approved by the University of California, San Francisco, Committee on Animal Research. The rabbits were housed singly in cages in a room with a constant temperature and a 12-hour light/dark cycle and fed a commercial diet (Purina Rabbit Chow, Ralston-Purina) with water ad libitum.
Surgical Procedures
For surgical preparation, rabbits were anesthetized with a mixture of xylazine (Lloyd Laboratories, 5 mg/kg IM) and ketamine (Parke-Davis, 50 mg/kg IM). Sterile technique was used, and ampicillin (10 mg/d IV) was given postoperatively.
Arterial and Venous Catheters
Two Tygon catheters were inserted into the right external jugular vein. A catheter consisting of silicone elastomer connected to PE-60 tubing was inserted into the right femoral artery. The catheters were led subcutaneously to the back of the neck and protected in the pockets of a nylon mesh jacket. The catheters were flushed with heparinized saline (1000 U/mL) at least every other day.
Aortic Nerve Section and Carotid Occluders
Three days after arterial and venous catheterization, a midline incision was made in the midcervical area to expose both common carotid arteries. The vagosympathetic sheath was incised longitudinally, and the aortic nerve, sympathetic trunk, and vagus were identified. To eliminate the buffering action of the aortic arch baroreceptors and maximize the responses to carotid occlusion, the aortic nerve was sectioned bilaterally. 8 - 9 Inflatable balloon vascular occluders (2 mm internal diameter, In Vivo Metric) were placed around both carotid arteries. 7 The incision was closed, and the silicone elastomer tubing from the occluders was exteriorized along with the vascular catheters.
Renal Nerve Electrodes
Seven days after placement of the carotid occluders, electrodes were placed on the left renal nerve for recording of RSNA as described previously. 1013 The left kidney was exposed via a retroperitonea] approach through a left flank incision. With a dissecting microscope, a renal nerve was identified and carefully isolated. Polytetrafluoroethylene-coated multistrand stainless wire electrodes (A-M System, Inc) were placed on the nerve, and a ground lead was fixed to the tissue close to the electrodes. The nerve and recording electrodes assembly was covered in silicone gel (Sil Gel 504, Wacker-Chemie Gimble), and the electrodes were exteriorized at the back of the neck.
Data Acquisition
On the day of an experiment, a rabbit was placed inside the shielded cage, and continuous recordings of arterial pressure, heart rate (HR), and RSNA were begun. Arterial pressure and HR were monitored with a pressure transducer (Cobe Laboratories, Inc) and a custom-built cardiovascular analyzer. RSNA was amplified using a differential amplifier (model AM 502, Tektronix) with a band-pass filter (low, 100 Hz; high, 3 kHz), and the action potentials were filtered, rectified, and integrated using a custom-built envelope detector. Renal neurograms were photographed from an oscilloscope screen (model 7313, Tektronix). Arterial pressure, HR, and integrated RSNA were digitized at 100 Hz, stored, and analyzed with a PDP 11/23+ computer (Digital Equipment Corp) and displayed on a polygraph (Grass Instruments). Background noise was determined when nerve activity was eliminated by an infusion of phenylephrine (40 jug/kg per minute). This value was subtracted from all experimental values of RSNA.
Control values for mean arterial pressure (MAP), HR, and RSNA were taken as the 5-minute average before BCO or drug administration. The initial baseline value of integrated RSNA was defined as 100%. BCO was performed three times in each experimental condition. Each occlusion lasted 1 to 2 minutes, and at least 20 minutes elapsed between them. Data collected during the last minute of each occlusion were averaged and used for subsequent analysis.
Experimental Protocols

Effect of Losartan on the Responses to Carotid Occlusion
The effects of BCO on arterial pressure, HR, and RSNA were tested in seven rabbits. At least 20 minutes after three control responses to BCO had been obtained, the rabbits received a bolus intravenous injection (5 mg/kg) of the AT, receptor antagonist losartan (Du Pont Merck Pharmaceutical Co). Thirty minutes after the administration of losartan when arterial pressure, HR, and RSNA had stabilized at their new values, the effects of BCO were tested again.
Effect of Phenylephrine on the Responses to Carotid Occlusion
The effects of losartan were examined in three rabbits when its hypotensive action was reversed by administration of phenylephrine. This protocol lasted 5 hours, so losartan was administered as a bolus and infusion. After the control responses to BCO had been obtained, losartan was administered intravenously as a bolus of 5 mg/kg followed by infusion at 1 mg/kg per hour. After arterial pressure, HR, and RSNA had stabilized at their new values, the effects of BCO were tested again. A background intravenous infusion of phenylephrine at 5 Mg/kg per minute was started, and at least 20 minutes later, the effects of BCO were tested again.
Effect of Nitroprusside on the Responses to Carotid Occlusion
The effects of nitroprusside on the responses to BCO were compared with those of losartan in three rabbits. After the control responses to BCO had been obtained, nitroprusside was infused intravenously at 5 /xg/kg per minute. After arterial pressure, HR, and RSNA had stabilized at their new values, the effects of BCO were tested again. Losartan was then administered intravenously as a bolus of 5 mg/kg followed by infusion at 1 mg/kg per hour, and after arterial pressure, HR, and RSNA had stabilized at their new values, the effects of BCO were tested again. 
control (P<.0l).
Reproducible responses were obtained when BCO was repeated 10 times over a 5-hour period.
Effect of Losartan on the Responses to Carotid Occlusion
Losartan decreased MAP from 75 ±2 to 66 ±2 mm Hg (/><.01), increased RSNA to 143±13% of control (P<.05), but did not change HR (286±8 to 282±9 bpm, P=A0) (Figs 2 and 3) . Losartan markedly attenuated (P<.0l) the MAP (66±2 to 81±2 mm Hg), HR (282±9 to 289±7 bpm), and RSNA (143±13% to 159±15% of control) responses to BCO (Figs 2 and 3) .
Effect of Phenylephrine on the Responses to Carotid Occlusion
Under control conditions, BCO increased MAP from 79±9 to 136±9 mmHg (P<.01), HR from 291±9 to 317±8 bpm (P<.05), and RSNA to 167±11% of control (P<.05) (Fig 4) . Losartan again decreased MAP from 79±9 to 73±4 mm Hg (P<.05), increased RSNA to 160±ll% of control (P<.0l), and attenuated (P<.05) the MAP, HR, and RSNA responses to BCO. When an infusion of phenylephrine was superimposed on the losartan infusion, MAP increased from 73±5 to 85±4 mm Hg (P<.05), HR tended to decrease from 304±16 to 278+21 bpm (P=.O7), and RSNA decreased from 160±ll% to 84±11% of control (P<.01). However, phenylephrine did not restore the MAP, HR, or RSNA responses to BCO (Fig 4) .
Effect of Nitroprusside on the Responses to Carotid Occlusion
Under control conditions, BCO increased (P<.05) MAP from 75±7 to 122±5 mm Hg, HR from 313±22 to 347 + 19 bpm, and RSNA to 132±7% of control ( Fig  5) . Infusion of nitroprusside decreased MAP from 75±7 to 67±5 mm Hg (P<.05) and tended to increase HR and RSNA. In contrast to losartan, however, nitroprusside did not significantly alter the MAP (67±5 to 115±6 mmHg) or RSNA (139±31% to 163±27% of control) response to BCO but tended to decrease the HR (330±9 to 350±9 bpm) response. When losartan was superimposed on the nitroprusside infusion, MAP, HR, and RSNA did not change significantly. However, under these conditions losartan again attenuated (P<.05) the MAP, HR, and RSNA responses to BCO (Fig 5) . 
Discussion
In a previous study 7 we demonstrated that inhibition of the renin-angiotensin system with the angiotensinconverting enzyme inhibitor captopril markedly attenuates the cardiovascular responses to BCO. This attenuation could be reversed by Ang II replacement, suggesting that it resulted from a reduction in endogenous Ang II levels. However, a role of increased levels of kinins or vasodilator prostaglandins could not be completely ruled out. The present finding that blockade of AT, receptors by Iosartan also attenuates the cardio-
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?225 §200 vascular responses to BCO argues against a role of kinins or vasodilator prostaglandins and provides evidence that AT, receptors play an important physiological role in facilitating the cardiovascular responses to BCO.
In our previous study 7 we proposed that the attenuation of the cardiovascular responses to BCO resulted at least in part from removal of a presynaptic action of Ang II to facilitate the sympathetic response to BCO. Other studies 1417 also support the concept that Ang II facilitates sympathetic activity by a presynaptic action.
Although this action could be exerted at various sites, including sympathetic nerve endings, autonomic ganglia, or the central nervous system, the site and mechanism by which inhibition of the renin-angiotensin system attenuated the cardiovascular responses to BCO in our previous study were not identified. The present finding that losartan attenuated the RSNA response to BCO suggests that this facilitation results from a central action of Ang II. Furthermore, the attenuation of cardiovascular responses to BCO by inhibition of the renin-angiotensin system can be accounted for on the basis of inhibition of sympathetic nerve response to BCO.
It should be considered that the attenuation of the RSNA response to BCO by losartan was due to its hypotensive action. However, restoration of RSNA to the prelosartan levels by administration of phenylephrine did not restore the RSNA response to BCO. We also demonstrated that a reduction in arterial pressure by nitroprusside did not attenuate the pressor or RSNA responses to BCO. It is therefore unlikely that the attenuation of the RSNA response to BCO by losartan was due to its hypotensive action.
In conclusion, the present study demonstrates that blockade of AT, receptors with losartan attenuates the cardiovascular and RSNA responses to BCO in conscious rabbits. These results suggest that endogenous Ang II facilitates the sympathetic response to BCO by an action on central AT, receptors and that blockade of this facilitation can account for the attenuation of the cardiovascular responses to BCO by inhibition of the renin-angiotensin system. Thus, the present study provides additional evidence that the Ang II-sympathetic interaction is physiologically important in cardiovascular regulation.
